Related Articles
L'Oréal's Strategic Investment in Amouage Signals Growth in Luxury Fragrance Market
In 2024, L’Oréal quietly acquired a minority stake in Amouage, an Omani high-end fragrance brand founded in 1983, overshadowed by its partnership with Jacquemus. Announced alongside annual results on February 7, this investment aligns with L’Oréal’s strategic portfolio sharpening, which also included acquiring the Miu Miu license and Korean brand Dr.G, and stakes in Galderma. Amouage, known for its use of rare, high-quality ingredients, reported a 24% growth in 2024, with sales more than doubling over three years to surpass USD 210 million. Financial details of the Amouage transaction were not disclosed. L’Oréal's CEO, Nicolas Hieronimus, highlighted advancements in AI, IT harmonization, and organizational simplification as part of making L’Oréal future-fit.
Unveiling L’Oréal’s Strategic Expansion into Medical Aesthetics and Nutricosmetics
L'Oréal, the French beauty giant, is expanding into the medical aesthetics market, reportedly exploring investments in botox and related treatments. The company has acquired stakes in medical clinics in China and North America and purchased a 10% stake in injectables firm Galderma last August. Additionally, L'Oréal is venturing into the nutricosmetics market, with its first product launch expected this year. This diversification strategy aims to broaden L'Oréal's portfolio and tap into new growth opportunities. The moves reflect the company's ambition to explore emerging markets and enhance its position in the beauty and wellness sectors.
Johnson & Johnson Faces Major Legal Challenge in UK over Talc Safety Concerns
Johnson & Johnson faces a new talc lawsuit in the UK, with around 3,500 claimants preparing to file in the high court. Represented by KP Law, the case accuses the company of failing to warn consumers about alleged asbestos contamination in its talc products. This marks the first such legal action in the British legal system. Kenvue, which now owns the talc business, expressed sympathy for cancer sufferers but maintains that scientific evidence does not support claims that their talc-based powder causes cancer. The lawsuit underscores ongoing global scrutiny of Johnson & Johnson’s product safety.